A community of peptide users for peptide users - honest experiences, help with safe handling, and an evidence-based Vendor-Radar against scammers.
From the founder
Glad you’re here. I’m Samuel - a family man and IT entrepreneur who knows the personal battle with weight, and who got scammed while searching for answers. That’s how Peptipedia was born: a place that protects and informs instead of selling.
- Samuel
Our core: advice and protection around ordering peptides. Have a specific vendor checked with an on-demand vendor audit, and see the documented Vendor-Radar - so you don’t lose money to scammers.
Reconstitute and dose correctly with the free injection calculator - units, draw volume, injections per vial.
A source-backed peptide library: effects, evidence level and key facts - one page per peptide.
An honest community - and Godot, our transparent AI expert who answers with real sources, never sales links.
Free with your account
Support for using your peptides safely: reconstitute your vial, keep an eye on its age and shelf life, log every dose - and always see how many injections are left.
22.06.2026
Tirzepatide (Zepbound) is the first drug approved by the FDA for obstructive sleep apnea (OSA) in adults with obesity. The SURMOUNT-OSA trial shows up to 63% reduction in apnea-hypopnea index.
22.06.2026
On January 13, 2026, the FDA officially confirmed that GLP-1 drugs like semaglutide and tirzepatide do not increase suicide risk. The suicide warning is being removed from drug labels.
21.06.2026
Three new scam vendors have been verified on the Vendor Radar, while the FDA warns of counterfeit Ozempic (semaglutide) in the supply chain and launches Import Alert 66-80 against illegal GLP-1 imports. An overview of current risks for peptide buyers.
18.06.2026
The FDA sent a third wave of 25 warning letters to telehealth companies in mid-June 2026 for misleading claims about compounded GLP-1 drugs. The agency warns patients about unapproved copycat products.
14.06.2026
A new Chainalysis report reveals the gray-market peptide crypto ecosystem has surpassed $100 million annually, with former fentanyl precursor suppliers entering the space and independent safety testing collapsing.
10.06.2026
A prespecified analysis of the SELECT trial (The Lancet, October 2025) reveals that semaglutide reduces major adverse cardiovascular events by 20% - and this benefit is largely independent of baseline weight or amount of weight lost.
